# Neo-Healer (NCT06747338)

> A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer

No report yet. It can be ordered.

- Drugs tested: anbenitamab plus HB1801
- Indication: early or locally advanced HER2-positive breast cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06747338
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Shanghai JMT-Bio Inc.
- Conditions: Early or Locally Advanced HER2-positive Breast Cancer
- Interventions: KN026; HB1801; Pertuzumab; Trastuzumab; Docetaxel; Carboplatin
- Enrollment: 520
- Primary outcome: tpCR (BIRC, AJCC 8th)

## Indexed commentary on Neo-Healer so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 6
- YouTube: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=neo-healer-nct06747338